New Research: Mitochondrial DNA in TRALI and Venetoclax-Obinituzumab in CLL Trials
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
New Research: Mitochondrial DNA in TRALI and Venetoclax-Obinituzumab in CLL Trials
-
Narrated by:
-
By:
About this listen
In this week's episode, associate editor Dr. James Griffin interviews researchers Dr. John Semple and Dr. Othman Al-Sawaf on their groundbreaking studies on transfusion-related acute lung injury and chronic lymphocytic leukemia treatment. Dr. Semple explored how mitochondrial DNA could act as a first hit in lung injury, while Dr. Al-Sawaf revealed that patient fitness may not significantly impact the efficacy of targeted CLL treatments. Both studies challenge existing medical assumptions and suggest new approaches to understanding disease mechanisms and treatment responses.
Featured Articles
- The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL
- Mitochondrial DNA via recipient TLR9 acts as a potent first-hit in murine transfusion-related acute lung injury (TRALI)
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.